Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Détails

ID Serval
serval:BIB_51A72FDD4A6F
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.
Périodique
Journal of Clinical Oncology
Auteur(s)
Advani Anjali, Coiffier Bertrand, Czuczman Myron S., Dreyling Martin, Foran James, Gine Eva, Gisselbrecht Christian, Ketterer Nicolas, Nasta Sunita, Rohatiner Ama, Schmidt-Wolf Ingo G. H., Schuler Martin, Sierra Jorge, Smith Mitchell R., Verhoef Gregor, Winter Jane N., Boni Joseph, Vandendries Erik, Shapiro Mark, Fayad Luis
ISSN
1527-7755[electronic], 0732-183X[linking]
Statut éditorial
Publié
Date de publication
2010
Volume
28
Numéro
12
Pages
2085-2093
Langue
anglais
Résumé
PURPOSE Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized anti-CD22 antibody conjugated to calicheamicin, a potent cytotoxic agent. This was a phase I study to determine the maximum-tolerated dose (MTD), safety, and preliminary efficacy of inotuzumab ozogamicin in an expanded MTD cohort of patients with relapsed or refractory CD22(+) B-cell non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS Inotuzumab ozogamicin was administered intravenously as a single agent once every 3 or 4 weeks at doses ranging from 0.4 to 2.4 mg/m(2). Outcomes included MTD, safety, pharmacokinetics, response, progression-free survival (PFS), and overall survival. Results Seventy-nine patients were enrolled. The MTD was determined to be 1.8 mg/m(2). Common adverse events at the MTD were thrombocytopenia (90%), asthenia (67%), and nausea and neutropenia (51% each). The objective response rate at the end of treatment was 39% for the 79 enrolled patients, 68% for all patients with follicular NHL treated at the MTD, and 15% for all patients with diffuse large B-cell lymphoma treated at the MTD. Median PFS was 317 days (approximately 10.4 months) and 49 days for patients with follicular NHL and diffuse large B-cell lymphoma, respectively. CONCLUSION Inotuzumab ozogamicin has demonstrated efficacy against CD22(+) B-cell NHL, with reversible thrombocytopenia as the main toxicity.
Mots-clé
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal/administration & dosage, Antibodies, Monoclonal/adverse effects, Antigens, CD22/immunology, Antineoplastic Agents/administration & dosage, Antineoplastic Agents/adverse effects, Disease-Free Survival, Europe, Female, Humans, Immunotoxins/administration & dosage, Immunotoxins/adverse effects, Infusions, Intravenous, Kaplan-Meiers Estimate, Lymphoma, Follicular/drug therapy, Lymphoma, Follicular/immunology, Lymphoma, Large B-Cell, Diffuse/drug therapy, Lymphoma, Large B-Cell, Diffuse/immunology, Male, Maximum Tolerated Dose, Middle Aged, Pilot Projects, Time Factors, Treatment Outcome
Pubmed
Web of science
Création de la notice
06/05/2010 15:05
Dernière modification de la notice
03/03/2018 17:11
Données d'usage